Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer

Journal of Cellular Biochemistry

Volumn 111, Issue 5, 2010, Pages 1082-1086

  Chen, Jiezhong ^a   Huang, Xu Feng ^a   Katsifis, Andrew ^b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

BRAF; EGFR; KRAS; PIK3CA; Src

Indexed keywords

B RAF KINASE; CETUXIMAB; DASATINIB; FLUOROURACIL; FOLINIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PANITUMUMAB; SOMATOMEDIN;

CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ACTIVATION; DRUG BINDING; DRUG EFFICACY; GENE MUTATION; HUMAN; OBESITY; ONCOGENE K RAS; ONCOGENE SRC; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT RESPONSE;

COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 78649854654     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22905     Document Type: Review

References (58)

1. American Cancer Society website. Cancer Facts and Figures. 2008.
2. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL,. 2009. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27 (12): 2091-2096.
3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD,. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (10): 1626-1634.
4. Baselga J,. 2001. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37 (Supplement 4): 16-22.
5. Benvenuti SS-BA, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A,. 2007a. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67 (6): 2643-2648.
6. Benvenuti SS-BA, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A,. 2007b. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67 (6): 2643-2648.
7. Boerner JL,. 2009. Role of Src family kinases in acquired resistance to EGFR therapies in cancer. Cancer Biol Ther 8 (8): 704-706.
8. Bokemeyer CBI, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P,. 2009. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27 (5): 663-671.
9. Bouali SCA, Ramacci C, Rouyer M, Becuwe P, Merlin JL,. 2009. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep 21 (3): 731-735.
10. Calle EE, Kaaks R,. 2004. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (8): 579-591.
11. Cappuzzo FFG, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M,. 2008. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19 (4): 717-723.
12. Chen J,. 2008. Is Src the key to understanding metastasis and developing new treatments for colon cancer? Nat Clin Pract Gastroenterol Hepatol 5 (6): 306-307.
13. Chen J, Huang XF,. 2009. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther 8 (14): 1313-1317.
14. Chen J, McMillan NA,. 2007. Multiple signal pathways in the leukemogenesis and therapeutic implications. Leuk Res 31 (12): 1759-1760.
15. Fenton JI, Birmingham JM, Hursting SD, Hord NG,. 2008. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer 122 (11): 2437.
16. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L,. 2007. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97 (8): 1139-1145.
17. Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, Inamori M, Nakajima N, Watanabe M, Kubota N, Yamauchi T, Kadowaki T, Wada K, Nakagama H, Nakajima A,. 2008. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 57 (11): 1531-1538.
18. Gao Y, Kitagawa K, Hiramatsu Y, Kikuchi H, Isobe T, Shimada M, Uchida C, Hattori T, Oda T, Nakayama K, Nakayama KI, Tanaka T, Konno H, Kitagawa M,. 2006. Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis. Cancer Res 66 (24): 11623-11631.
19. Huang XF, Chen J,. 2009. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes Rev 10 (6): 610-616.
20. Huang SMLJ, Armstrong EA, Harari PM,. 2002. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62 (15): 4300-4306. (Pubitemid 34827286)
21. Irby RBMW, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ,. 1999. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21 (2): 187-190.
22. Jhawer MGS, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM,. 2008. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68 (6): 1953-1961.
23. Jin Q, Esteva FJ,. 2008. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13 (4): 485-498.
24. Jonker DJOCC, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ,. 2007. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 (20): 2040-2048.
25. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW,. 2003. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284 (1): 31-53.
26. Kinzler KW, Vogelstein B,. 1996. Lessons from hereditary colorectal cancer. Cell 87 (2): 159-170.
27. Kopetz S,. 2007. Targeting SRC and epidermal growth factor receptor in colorectal cancer: Rationale and progress into the clinic. Gastrointest Cancer Res 1 (4 Suppl 2): S37-S41.
28. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche O, Reid J, Stone S, Penault-Llorca F,. 2009. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27 (35): 5924-5930.
29. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL,. 2009. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28 (43): 3801-3813.
30. Liàvre ABJ, Le Corre D, Boige V, Landi B, Emile JF, Càté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P,. 2006. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (8): 3992-3995.
31. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A,. 2009. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27 (16): 2622-2629.
32. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z,. 2007. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67 (17): 8240-8247.
33. Meyerhardt JA, Mayer RJ,. 2005. Systemic therapy for colorectal cancer. N Engl J Med 352 (5): 476-487.
34. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A,. 2005. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 6 (5): 279-286.
35. Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, Pedrazzi G, Ardizzoni A,. 2010. PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102 (1): 162-164.
36. Normanno NTS, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F,. 2009. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6 (9): 519-527.
37. Patel DBR, Hooper A, Prewett M, Hicklin DJ, Kang X,. 2009. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol 34 (1): 25-32.
38. Perkins GLA, Ramacci C, Méatchi T, de Reynies A, Emile JF, Boige V, Tomasic G, Bachet JB, Bibeau F, Bouché O, Penault-Llorca F, Merlin JL, Laurent-Puig P,. 2010. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer 127 (6): 1321-1331.
39. Perrone FLA, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S,. 2009. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20 (1): 84-90.
40. Plesec TPHJ,. 2009. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 16 (4): 196-203.
41. Pollak M,. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8 (12): 915-928.
42. Saltz LB,. 2009. Looking ahead: What will change in colorectal cancer treatment? Gastrointest Cancer Res 3 (2 Suppl): S16-S18.
43. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE,. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (5670): 554. (Pubitemid 38541907)
44. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A,. 2009. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69 (5): 1851-1857.
45. Scartozzi MMA, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, Galizia E, Giustini L, Silva RR, Bisonni R, Berardi R, Biagetti S, Menzo S, Falcone A, Bearzi I, Cascinu S,. 2010. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 127 (8): 1941-1947.
46. Shendure J, Ji H,. 2008. Next-generation DNA sequencing. Nat Biotechnol 26 (10): 1135-1145.
47. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C,. 2003. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 55 (3): 713-723.
48. Sridhar SS, Goodwin PJ,. 2009. Insulin-insulin-like growth factor axis and colon cancer. J Clin Oncol 27 (2): 165-167.
49. Tabernero JVCE, Díaz-Rubio E, Cervantes A, Humblet Y, André T, Van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A,. 2007. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25 (33): 5225-5232.
50. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T,. 2005. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11 (16): 5878-5885.
51. Van Cutsem EPM, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG,. 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 252 (13): 1658-1664.
52. Van Cutsem EKC, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P,. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (14): 1408-1417.
53. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC,. 2009. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: Implications for cancer therapy. Curr Cancer Drug Targets 9 (6): 748-760.
54. Wainberg ZHJ,. 2006. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 5 (5): 363-367.
55. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM,. 2009. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8 (8): 696-703.
56. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS,. 2009. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27 (2): 176-185.
57. Wu XRM, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J,. 1996. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12 (7): 1397-1403.
58. Yamatodani T, Ekblad L, Kjellén E, Johnsson A, Mineta H, Wennerberg J,. 2009. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 135 (3): 395-402.